Rapid Micro Biosystems Inc(RPID) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 2 at 4:00 PM ET (Korea 11/3 06:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.12 | Insider Own | 47.41% | Shs Outstand | 45.5M | Perf Week | -10.47% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | 24.14% | Insider Trans | - | Shs Float | 26.4M | Perf Month | -23.61% |
| Enterprise Value | 0.04B | PEG | - | EPS next Q | -0.2 | Inst Own | 24.59% | Short Float | 3.37% | Perf Quarter | -65.88% |
| Income | -0.05B | P/S | 1 | EPS this Y | 10.24% | Inst Trans | -3.24% | Short Ratio | 3.59 | Perf Half Y | -71.78% |
| Sales | 0.04B | P/B | 1.98 | EPS next 5Y | 23.23% | ROA | -76.4% | Short Interest | 0.89M | Perf YTD | -75.77% |
| Book/sh | 0.36 | P/C | 1.78 | EPS past 3/5Y | 9.7% 2.04% | ROE | -141.65% | 52W High | -85.77% ($4.94) | Perf Year | -76.49% |
| Cash/sh | 0.39 | P/FCF | - | Sales past 3/5Y | 25.15% 15.88% | ROIC | -128.81% | 52W Low | 0.4% ($0.70) | Perf 3Y | -30.76% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -11.56% | Gross Margin | 5.54% | Volatility(W/M) | 6.69% 8.81% | Perf 5Y | -96.71% |
| Dividend TTM | - | EV/Sales | 1.1 | Sales Y/Y TTM | 16.13% | Oper. Margin | -141.45% | ATR (14) | 0.07 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.48 | EPS Q/Q | -0.64% | Profit Margin | -145.56% | RSI (14) | 24.11 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.52 | Sales Q/Q | 10.91% | SMA20 | -13.86% ($0.81) | Beta | 1.53 | Target Price | $5.75 |
| Payout | - | Debt/Eq | 1.31 | Earnings | 2026/8/7 | SMA50 | -34.57% ($1.07) | Rel Volume | 0.31 | Prev Close | $0.74 |
| Employees | 171 | LT Debt/Eq | 1.24 | EPS/Sales Surpr. | -10.97% 2.27% | SMA200 | -68.43% ($2.22) | Avg Volume(3M) | 0.25M | Price | $0.7 |
| IPO | 2021/7/15 | Option/Short | No/Yes | Trades | 363 | Volume | 77,265 | Change | -4.5% |
🔬 A U.S. life sciences equipment company that supplies automated rapid microbial detection systems used in quality control at pharmaceutical, medical device, and personal care product manufacturing facilities. Founded in 2006, its core asset is the Growth Direct platform, which captures the autofluorescence of living cells with a camera and detects microbial growth faster than traditional methods that rely on the human eye.
Over the past 1 year, on the lower side
86% below its 1-year high.
Traded less than usual. That is 31% of its average volume.
RPID has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +10.2% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $100. Peers typically go for $145.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -96.7%. The S&P 500 did +63% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 24.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #102 of 140 in the industry
Based on market cap of $35M.
XTNT#98 Xtant Medical Holdings Inc $39M PER - 
CVRX#99 CVRx Inc $36M PER - 
ELUT#100 Elutia Inc $36M PER - 
TELA#101 TELA Bio Inc $36M PER - RPID#102 Rapid Micro Biosystems Inc $35M PER - 
FAQ
What kind of company is RPID?
RPID belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of RPID?
The market cap of RPID is approximately $35M, ranking 5,007 within its sector.
What is the 52-week high and low for RPID?
RPID has recorded a 52-week high of $4.94 and a low of $0.70.
